PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Overview: Alpha-1 antitrypsin deficiency • Pathophysiology • Symptoms • Diagnosis • Management PART 06: Overview: Alpha-1 antitrypsin drugs • Components of blood plasma • Regulation of plasma therapeutics • Regulatory authorities • Reimbursement PART 07: Pipeline analysis • D1-AAT • B1-AAT • C1-AAT • rAAV1-CB-hAAT • G1-AAT • L1-AAT • ARC-AAT • AAT • PTB-101 SDF Alpha • ALN-AAT PART 08: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 09: Market segmentation by route of administration • Parenteral • Inhalation PART 10: Geographical segmentation • Global alpha-1 antitrypsin drugs market by geography 2015-2020 • Alpha-1 antitrypsin drugs market in Americas • Alpha-1 antitrypsin drugs market in EMEA • Alpha-1 antitrypsin drugs market in APAC PART 11: Market drivers • Improved diagnosis of AATD • Improving economic conditions • Novel product opportunities • High unmet needs PART 12: Impact of drivers PART 13: Market challenges • Stringent regulations • Limited plasma fractionation capacity • Shortage of alpha-1 antitrypsin supply • High cost of drugs PART 14: Impact of drivers and challenges PART 15: Market trends • Strategic alliances and M&A • Patient assistance programs • Increasing awareness about therapy PART 16: Vendor landscape • Competitive scenario • Market share analysis 2015 • Baxter International • CSL Behring • Grifols • Kamada • Other prominent vendors PART 17: Appendix • List of abbreviations PART 18: Explore Technavio List of Exhibits Exhibit 01: Product offerings Exhibit 02: Common symptoms of AATD Exhibit 03: Blood plasma composition Exhibit 04: Plasma proteins composition by percentage share Exhibit 05: Process of derivation of alpha-1 antitrypsin from plasma Exhibit 06: Regulatory policies of plasma proteins therapeutics Exhibit 07: Global alpha-1 antitrypsin drugs market: Products in pipeline Exhibit 08: Global alpha-1 antitrypsin drugs market 2015-2020 ($ billions) Exhibit 09: Five forces analysis Exhibit 10: Global alpha-1 antitrypsin drugs market by geography 2015 Exhibit 11: Global alpha-1 antitrypsin drugs market by geography 2015-2020 ($ millions) Exhibit 12: Alpha-1 antitrypsin drugs market in Americas 2015-2020 ($ millions) Exhibit 13: Alpha-1 antitrypsin drugs market in EMEA 2015-2020 ($ millions) Exhibit 14: Alpha-1 antitrypsin drugs market in APAC 2015-2020 ($ millions) Exhibit 15: Global alpha-1 antitrypsin drugs market: YoY growth and revenue based on geography 2015-2020 Exhibit 16: Impact of drivers Exhibit 17: Impact of drivers and challenges Exhibit 18: Global alpha-1 antitrypsin drugs market share analysis 2015 Exhibit 19: Baxter International: Business segmentation by revenue 2014 Exhibit 20: Baxter International: YoY growth rate and revenue of BioScience segment 2012-2014 ($ billions) Exhibit 21: Baxter International: YoY growth rate and revenue of Glassia in the US, Canada, Australia and New Zealand 2012-2014 ($ millions) Exhibit 22: Baxter International: Key takeaways Exhibit 23: CSL Behring: Sales by area of therapy 2014 Exhibit 24: CSL Behring: Key takeaways Exhibit 25: Grifols: YoY growth rate and revenue of bioscience segment 2012-2014 ($ billions) Exhibit 26: Grifols: Key takeaways Exhibit 27: Kamada: Business segmentation by revenue 2014 Exhibit 28: Kamada: YoY growth rate and revenue of Glassia (excluding US, Canada, Australia, and New Zealand) 2012-2014 ($ millions) Exhibit 29: Kamada: Key takeaways

Baxter International, CSL Behring, Grifols, Kamada, Abeona Therapeutics, Alnylam Pharmaceuticals, Applied Genetic Technologies, Arrowhead Research, Baxalta, Biogen, Chiesi, Curaxys, Laboratoire français du Fractionnement et des Biotechnologies, ProBioGen, ProMetic Life Sciences.